. Author manuscript; available in PMC: 2011 Dec 4.

Published in final edited form as: Arterioscler Thromb Vasc Biol. 2005 Dec 8;26(2):385–391. doi: 10.1161/01.ATV.0000199248.53590.e1

TABLE 2.

Individual ApoA-I Kinetic Parameters in Participating Subjects at the End of the Placebo, Estrogen, and Estrogen Plus Progestin Treatment Phases

Subject	Pool Size, mg			FCR, pools/d			PR, mg/kg per day
Subject	Placebo	CEE	CEE+MPA	Placebo	CEE	CEE+MPA	Placebo	CEE	CEE+MPA
1	3077	4051	3577	0.196	0.296	0.257	9.11	18.08	13.99
2	4768	4926	4698	0.217	0.272	0.248	13.01	17.13	14.56
3	3909	5298	4816	0.165	0.185	0.234	7.93	12.07	13.89
4	3695	5197	4220	0.186	0.313	0.283	8.53	19.72	14.39
5	4563	5397	4880	0.184	0.174	0.166	12.98	14.7	13.12
6	4345	4415	4226	0.208	0.166	0.142	14.66	12.18	9.99
7	ND	3442	2707	ND	0.177	0.194	ND	11.48	10.25
8	5411	5945	5938	0.257	0.274	0.244	14.47	17.24	15.33
Mean^*	4252	5033	4622	0.202	0.240	0.225	11.52	15.87	13.61
SD^*	766	634	736	0.029	0.063	0.051	2.90	2.96	1.73
% Change vs placebo		+20	+9		+20	+13		+47	+26
P value vs placebo		0.010	0.036		0.142	0.329		0.045	0.201
% Change, vs CEE			−8			−5			−13
P value, vs CEE			0.013			0.231			0.037

ND indicates not determined.

Mean and SD calculated after exclusion of subject 7.